High incidence and viral load of HHV-6A in a multi-centre kidney transplant cohort.

BK viraemia CMV (citomegalovirus) HHV-6A/B epstein—barr virus renal tranplantation transplant outcome

Journal

Frontiers in transplantation
ISSN: 2813-2440
Titre abrégé: Front Transplant
Pays: Switzerland
ID NLM: 9918573988006676

Informations de publication

Date de publication:
2023
Historique:
received: 17 03 2023
accepted: 08 06 2023
medline: 12 7 2024
pubmed: 12 7 2024
entrez: 12 7 2024
Statut: epublish

Résumé

Human herpesvirus 6 (HHV-6) is a common opportunistic pathogen in kidney transplant recipients. Two distinct species of HHV-6, HHV-6A and HHV-6B, have been identified, of which the latter seems to be dominant. However, it is unclear whether they increase the likelihood of other viral reactivations. We characterized a multi-centre cohort of 93 patients along nine study visits for viral load. We tested for the following viruses: HHV-6A and HHV-6B, the herpesviruses cytomegalovirus (CMV) and Epstein-Barr virus (EBV) and the polyomavirus BK (BKV). We detected HHV-6A viral load in 48 (51.6%) patients, while the incidence of HHV-6B was much lower, being detected in 6 (6.5%) patients. The incidence of HHV-6A was higher than of BKV, CMV and EBV. HHV-6A also demonstrated higher viral loads than the rest of viruses. There was a non-significant trend of association between HHV-6A and HHV-6B as co-infection, whereas no increased incidence of other viruses among patients with HHV-6A reactivation was observed. There was no negative effect of high HHV-6A (>10,000 copies/ml) load on markers of renal graft and hepatic function or blood count twelve months post-transplant. In contrast to previously published data, our results show a clear dominance of HHV-6A in peripheral blood when compared to HHV-6B, with higher incidence and viral load levels. Despite the high HHV-6A loads observed, we did not identify any negative effects on posttransplant outcome.

Identifiants

pubmed: 38993901
doi: 10.3389/frtra.2023.1188535
pmc: PMC11235347
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1188535

Informations de copyright

© 2023 Blazquez-Navarro, Roch, Wehler, Kaliszczyk, Bauer, Thieme, Rosiewicz, Stervbo, Anft, Reinke, Hugo, Zgoura, Viebahn, Westhoff, Or-Guil and Babel.

Déclaration de conflit d'intérêts

CB was employed by MicroDiscovery GmbH. The authors PR and NB declared that they were editorial board members of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Arturo Blazquez-Navarro (A)

Berlin Center for Advanced Therapies (BeCAT), Charité-Universitätsmedizin Berlin, Berlin, Germany.
Center for Translational Medicine, Universitätsklinikum der Ruhr-Universität Bochum, Medizinische Klinik I, Herne, Germany.

Toralf Roch (T)

Berlin Center for Advanced Therapies (BeCAT), Charité-Universitätsmedizin Berlin, Berlin, Germany.
Center for Translational Medicine, Universitätsklinikum der Ruhr-Universität Bochum, Medizinische Klinik I, Herne, Germany.

Patrizia Wehler (P)

Berlin Center for Advanced Therapies (BeCAT), Charité-Universitätsmedizin Berlin, Berlin, Germany.
Center for Translational Medicine, Universitätsklinikum der Ruhr-Universität Bochum, Medizinische Klinik I, Herne, Germany.

Sviatlana Kaliszczyk (S)

Berlin Center for Advanced Therapies (BeCAT), Charité-Universitätsmedizin Berlin, Berlin, Germany.
Center for Translational Medicine, Universitätsklinikum der Ruhr-Universität Bochum, Medizinische Klinik I, Herne, Germany.

Chris Bauer (C)

MicroDiscovery GmbH, Berlin, Germany.

Constantin Thieme (C)

Berlin Center for Advanced Therapies (BeCAT), Charité-Universitätsmedizin Berlin, Berlin, Germany.

Kamil S Rosiewicz (KS)

Berlin Center for Advanced Therapies (BeCAT), Charité-Universitätsmedizin Berlin, Berlin, Germany.

Ulrik Stervbo (U)

Berlin Center for Advanced Therapies (BeCAT), Charité-Universitätsmedizin Berlin, Berlin, Germany.
Center for Translational Medicine, Universitätsklinikum der Ruhr-Universität Bochum, Medizinische Klinik I, Herne, Germany.

Moritz Anft (M)

Center for Translational Medicine, Universitätsklinikum der Ruhr-Universität Bochum, Medizinische Klinik I, Herne, Germany.

Petra Reinke (P)

Berlin Center for Advanced Therapies (BeCAT), Charité-Universitätsmedizin Berlin, Berlin, Germany.

Christian Hugo (C)

Universitätsklinikum Carl Gustav Carus, Medizinische Klinik III-Bereich Nephrologie, Dresden, Germany.

Panagiota Zgoura (P)

Chirurgische Klinik, Universitätsklinikum Knappschaftskrankenhaus Bochum, Bochum, Germany.

Richard Viebahn (R)

Chirurgische Klinik, Universitätsklinikum Knappschaftskrankenhaus Bochum, Bochum, Germany.

Timm Westhoff (T)

Center for Translational Medicine, Universitätsklinikum der Ruhr-Universität Bochum, Medizinische Klinik I, Herne, Germany.

Michal Or-Guil (M)

Institute of Medical Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany.

Nina Babel (N)

Berlin Center for Advanced Therapies (BeCAT), Charité-Universitätsmedizin Berlin, Berlin, Germany.
Center for Translational Medicine, Universitätsklinikum der Ruhr-Universität Bochum, Medizinische Klinik I, Herne, Germany.

Classifications MeSH